Adverse Events Associated With Immune Checkpoint Inhibitors-Reply
JAMA
.
2019 Mar 26;321(12):1219-1220.
doi: 10.1001/jama.2018.22123.
Authors
Douglas B Johnson
1
,
Sunandana Chandra
2
,
Jeffrey A Sosman
2
Affiliations
1
Department of Medicine, Vanderbilt Ingram Cancer Center, Nashville, Tennessee.
2
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois.
PMID:
30912830
DOI:
10.1001/jama.2018.22123
No abstract available
Publication types
Letter
Comment
MeSH terms
Immunologic Factors*
Programmed Cell Death 1 Receptor*
Substances
Immunologic Factors
Programmed Cell Death 1 Receptor